CoChat
Sign Up
Cited by 203

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks

Domingues, Catarina, da Cruz e Silva, Odete A.B., Henriques, Ana Gabriela·2017·Current Alzheimer Research
DOI 10.2174/1567205014666170317113606PMC PMC5543563
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1567205014666170317113606

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 126

  1. [1]Kalaria R.N. Maestre G.E. Arizaga R. Friedland R.P. Galasko D. Hall K. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008 7 9 812 826 18667359 PMC2860610
  2. [2]Brookmeyer R. Gray S. Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 1998 88 9 1337 1342 9736873 PMC1509089
  3. [3]Harman D. Alzheimer’s disease pathogenesis: role of aging. Ann. N. Y. Acad. Sci. 2006 1067 1 454 460 16804026
  4. [4]Tanzi R.E. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012 2 1 10 PMC3475404 23028126
  5. [5]Da Cruz e Silva O.A. Henriques A.G. Domingues S.C. da Cruz e Silva EF. Wnt signalling is a relevant pathway contributing to amyloid beta-peptide-mediated neuropathology in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets 2010 9 720 726 20942790
  6. [7]Henriques A.G. Oliveira J.M. Carvalho L.P. da Cruz e Silva OAB. Aβ Influences cytoskeletal signaling cascades with consequences to Alzheimer’s disease. Mol. Neurobiol. 2015 52 1391 1407 25344315
  7. [8]Mandelkow E.M. Mandelkow E. Tau in Alzheimer’s disease. Trends Cell Biol. 1998 8 425 427 9854307
  8. [9]Gustke N. Steiner B. Mandelkow E.M. Biernat J. Meyer H.E. Goedert M. The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett. 1992 307 199 205 1644173
  9. [10]Alonso A.C. Zaidi T. Grundke-Iqbal I. Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994 91 5562 5566 8202528 PMC44036
  10. [11]Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 2003 24 8 1079 1085 14643379
  11. [14]Chung S-H. Aberrant phosphorylation in the pathogenesis of Alzheimer’s disease. BMB Rep. 2009 42 467 474 19712581
  12. [15]Vintém A.P. Henriques A.G. da Cruz e Silva OAB, da Cruz e Silva EF. PP1 inhibition by Aβ peptide as a potential pathological mechanism in Alzheimer’s disease. Neurotoxicol. Teratol. 2009 31 85 88 19028567
  13. [16]Blurton-Jones M. LaFerla F.M. Pathways by which Abeta facilitates tau pathology. Curr. Alzheimer Res. 2006 3 5 437 448 17168643
  14. [17]Sandbrink R. Masters C.L. Beyreuther K. Beta A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons. J. Biol. Chem. 1994 269 2 1510 1517 8288617
  15. [18]Wolfe M.S. Haass C. The role of presenilins in gama-secretase activity. J. Biol. Chem. 2001 276 5413 5416 11134059
  16. [19]Buxbaum J.D. Liu K.N. Luo Y. Slack J.L. Stocking K.L. Peschon J.J. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 1998 273 27765 27767 9774383
  17. [20]Allinson T.M. Parkin E.T. Turner A.J. Hooper N.M. ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 2003 74 342 352 14598310
  18. [22]Bennett B.D. Babu-Khan S. Loeloff R. Louis J.C. Curran E. Citron M. Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. 2000 275 20647 20651 10749877
  19. [23]Cai H. Wang Y. McCarthy D. Wen H. Borchelt D.R. Price D.L. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 2001 4 233 234 11224536
  20. [24]Cole S.L. Vassar R. The Alzheimer’s disease Beta-secretase enzyme, BACE1. Mol. Neurodegener. 2007 2 1 1 25 18005427 PMC2211305
  21. [25]Zhang H. Ma Q. Zhang Y. Xu H. Proteolytic processing of Alzheimer’s β‐amyloid precursor protein. J. Neurochem. 2012 120 Suppl. 1 9 21 22122372 PMC3254787
  22. [28]Henriques A.G. Domingues S.C. Fardilha M. da Cruz e Silva EF, da Cruz e Silva OA. Sodium azide and 2-deoxy-D-glucose-induced cellular stress affects phosphorylation-dependent AβPP processing. J. Alzheimers Dis. 2005 7 201 212 16006663
  23. [29]Domingues S.C. Henriques A.G. Wu W. da Cruz e Silva EF, da Cruz e Silva OAB. Altered subcellular distribution of the Alzheimer’s amyloid precursor protein under stress conditions. Ann. N. Y. Acad. Sci. 2007 1096 184 195 17405930
  24. [30]Henriques A.G. Vieira S.I. Crespo-López M.E. de Oliveira M.A. da Cruz e Silva EF, da Cruz e Silva OAB. Intracellular sAPP retention in response to Aβ is mapped to cytoskeleton-associated structures. J. Neurosci. Res. 2009 87 1449 1461 19105196
  25. [31]Henriques A.G. Vieira S.I. da Cruz e Silva EF, da Cruz e Silva OAB. Abeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. J. Mol. Neurosci. 2009 39 248 255 19340611 PMC2744832
  26. [32]Henriques A.G. Vieira S.I. da Cruz e Silva EF, da Cruz e Silva OAB. Abeta promotes Alzheimer’s disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. J. Neurochem. 2010 113 3 761 771 20345756
  27. [33]Meraz-Ríos M.A. Toral-Rios D. Franco-Bocanegra D. Villeda-Hernández J. Campos-Peña V. Inflammatory process in Alzheimer’s disease. Front. Integr. Nuerosci. 2013 7 59 1 15 PMC3741576 23964211
  28. [36]Oliveira J.M. Henriques A.G. Martins F. Rebelo S. da Cruz e Silva OAB. Amyloid-β modulates both AβPP and Tau phosphorylation. J. Alzheimers Dis. 2015 45 2 495 507 25589714
  29. [37]Shankar G.M. Walsh D.M. Alzheimer’s disease: synaptic dysfunction and Abeta. Mol. Neurodegener. 2009 4 1 13 19930651 PMC2788538
  30. [38]Rubio-Perez J.M. Morillas-Ruiz J.M. A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci. World J. 2012 2012 1 15 PMC3330269 22566778
  31. [39]Mrak R.E. Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 2005 26 3 349 354 15639313
  32. [42]Dzamba D. Harantova L. Butenko O. Anderova M. Glial Cells - The Key Elements of Alzheimer’s Disease. Curr. Alzheimer Res. 2016 13 8 894 911 26825092
  33. [44]Swardfager W. Lanctôt K. Rothenburg L. Wong A. Cappell J. Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol. Psychiatry 2010 68 10 930 941 20692646
  34. [45]Liu C. Cui G. Zhu M. Kang X. Guo H. Neuroinflammation in Alzheimer’s disease: chemokines produced by astrocytes and chemokine receptors. Int. J. Clin. Exp. Pathol. 2014 7 8342 8355 25674199 PMC4314046
  35. [47]Mattson M.P. Cheng B. Culwell A.R. Esch F.S. Lieberburg I. Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993 10 2 243 254 8094963
  36. [48]Ma T. Zhao Y. Kwak Y-D. Yang Z. Thompson R. Luo Z. Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J. Neurosci. 2009 29 36 11226 11236 19741129 PMC2757921
  37. [49]Combs C.K. Karlo J.C. Kao S.C. Landreth G.E. Beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 2001 21 4 1179 1188 11160388 PMC6762255
  38. [50]Lindberg C. Hjorth E. Post C. Winblad B. Schultzberg M. Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone. Neurotox. Res. 2005 8 267 276 16371321
  39. [52]Fiala M. Zhang L. Gan X. Sherry B. Taub D. Graves M.C. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol. Med. 1998 4 480 489 9713826 PMC2230332
  40. [53]Britschgi M. Wyss-Coray T. Systemic and acquired immune responses in Alzheimer’s disease. Int. Rev. Neurobiol. 2007 82 205 233 17678963
  41. [54]Bonotis K. Krikki E. Holeva V. Aggouridaki C. Costa V. Baloyannis S. Systemic immune aberrations in Alzheimer’s disease patients. J. Neuroimmunol. 2008 193 1-2 183 187 18037502
  42. [55]Tuppo E.E. Arias H.R. The role of inflammation in Alzheimer’s disease. Int. J. Biochem. Cell Biol. 2005 37 2 289 305 15474976
  43. [56]Zheng C. Zhou X-W. Wang J-Z. The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl. Neurodegener. 2016 5 1 15 27054030 PMC4822284
  44. [57]Luster A. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998 338 7 436 445 9459648
  45. [58]Owens T. Babcock A.A. Millward J.M. Toft-Hansen H. Cytokine and chemokine inter-regulation in the inflamed or injured CNS. Brain Res. Brain Res. Rev. 2005 48 178 184 15850656
  46. [59]Murphy P.M. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 2002 54 227 229 12037138
  47. [60]Le Thuc O. Blondeau N. Nahon J.L. Rovère C. The complex contribution of chemokines to neuroinflammation: Switching from beneficial to detrimental effects. Ann. N. Y. Acad. Sci. 2015 1351 127 140 26251227
  48. [61]Goldgaber D. Harris H.W. Hla T. Maciag T. Donnelly R.J. Jacobsen J.S. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 1989 86 19 7606 7610 2508093 PMC298115
  49. [62]Buxbaum J.D. Oishi M. Chen H.I. Pinkas-Kramarski R. Jaffe E.A. Gandy S.E. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 1992 89 21 10075 10078 1359534 PMC50280
  50. [64]Griffin W.S. Liu L. Li Y. Mrak R.E. Barger S.W. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflammation 2006 3 1 9 16542445 PMC1435743
  51. [67]Forloni G. Demicheli F. Giorgi S. Bendotti C. Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-I. Brain Res. Mol. Brain Res. 1992 16 128 134 1334190
  52. [68]Sheng J.G. Ito K. Skinner R.D. Mrak R.E. Rovnaghi C.R. van Eldik L.J. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol. Aging 1996 17 5 761 766 8892349 PMC3886636
  53. [69]Song C. Zhang Y. Dong Y. Acute and subacute IL-1 β administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for neuroprotection and neurodegeneration. J. Neuroinflammation 2013 10 59 1 15 23651534 PMC3656796
  54. [70]Ma G. Chen S. Wang X. Ba M. Yang H. Lu G. Short-term interleukin-1(beta) increases the release of secreted APP(alpha) via MEK1/2-dependent and JNK-dependent alpha-secretase cleavage in neuroglioma U251 cells. J. Neurosci. Res. 2005 80 5 683 692 15880353
  55. [71]Anderson P. Watts H. Jen S. Gentleman S.M. Moncaster J.A. Walsh D.T. Differential effects of interleukin-1β and S100B on amyloid precursor protein in rat retinal neurons. Clin. Ophthalmol. 2009 3 235 242 19668572 PMC2708995
  56. [72]Tachida Y. Nakagawa K. Saito T. Saido T.C. Honda T. Saito Y. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J. Neurochem. 2008 104 5 1387 1393 18021299
  57. [75]Gitter B.D. Cox L.M. Rydel R.E. May P.C. Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc. Natl. Acad. Sci. USA 1995 92 23 10738 10741 7479875 PMC40687
  58. [76]Bandyopadhyay S.M. Hartley D. M.Cahill C Debomay K Chattopadhyay N Rogers J. IL-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP Kinase. J. Neurosci. Res. 2006 84 106 118 16724341
  59. [77]Del Del-Bo R. Angeretti N. Lucca E. De Simoni M.G. Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and fl-amyloid production in cultures. Neurosci. Lett. 1995 188 70 74 7783982
  60. [78]Brugg B. Dubreuil Y.L. Huber G. Wollman E.E. Delhaye-Bouchaud N. Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc. Natl. Acad. Sci. USA 1995 92 7 3032 3035 7708769 PMC42353
  61. [79]Chakrabarty P. Jansen-West K. Beccard A. Ceballos-Diaz C. Levites Y. Verbeeck C. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010 24 2 548 559 19825975 PMC3083918
  62. [80]Sutinen E.M. Pirttilä T. Anderson G. Salminen A. Ojala J.O. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J. Neuroinflammation 2012 9 1 1 14 22898493 PMC3458954
  63. [81]Tweedie D. Sambamurti K. Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res. 2007 4 4 378 385 17908040
  64. [82]Sommer G. Kralisch S. Lipfert J. Weise S. Krause K. Jessnitzer B. Amyloid precursor protein expression is induced by tumor necrosis factor alpha in 3T3-L1 adipocytes. J. Cell. Biochem. 2009 108 6 1418 1422 19862700
  65. [83]Gabbita S.P. Johnson M.F. Kobritz N. Eslami P. Poteshkina A. Varadarajan S. Oral TNFα modulation alters neutrophil infiltration, improves cognition and diminishes tau and amyloid pathology in the 3xTgAD mouse model. PLoS One 2015 10 1 28 PMC4593589 26436670
  66. [84]Tweedie D. Ferguson R.A. Fishman K. Frankola K.A. Van Praag H. Holloway H.W. Tumor necrosis factor-α synthesis inhibitor 3,6 ′ - dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J. Neuroinflammation 2012 9 106 1 16 22642825 PMC3405480
  67. [85]Chakrabarty P. Herring A. Ceballos-diaz C. Das P. Golde T.E. Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. Mol. Neurodegener. 2011 6 16 1 10 21324189 PMC3050766
  68. [87]Cho H.J. Su Kyoung K. Min Jin S. Eun Mi H. Sik Kim Y. Kyoon H. IFN-gama-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia 2007 55 3 253 262 17091494
  69. [89]Kim Y-M. Im J.Y. Han S.H. Kang H.S. Choi I. IFN-gama up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages. J. Immunol. 2000 165 6 3198 3205 10975835
  70. [90]Joosten L.A. Radstake T.R. Lubberts E. van den Bersselaar L.A. van Riel P.L. van Lent P.L. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 2003 48 2 339 347 12571842
  71. [91]Okamura H Tsutsi H Komatsu T Yutsudo M Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995 378 6552 88 91 7477296
  72. [92]Kiyota T. Okuyama S. Swan R.J. Jacobsen M.T. Gendelman H.E. Ikezu T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J. 2010 24 8 3093 3102 20371618 PMC2909296
  73. [93]Latta C.H. Sudduth T.L. Weekman E.M. Brothers H.M. Abner E.L. Popa G.J. Determining the role of IL-4 induced neuroinflammation in microglial activity and amyloid-β using BV2 microglial cells and APP/PS1 transgenic mice. J. Neuroinflammation 2015 12 41 1 13 PMC4350455 25885682
  74. [94]Chakrabarty P. Tianbai L. Herring A. Ceballos-diaz C. Das P. Golde T.E. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol. Neurodegener. 2012 7 36 1 12 22838967 PMC3441281
  75. [95]Chakrabarty P. Andrew L. Ceballos-Diaz C. Eddy J. Funk C. Moore B. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 2015 85 3 519 533 25619653 PMC4320003
  76. [97]Chao C.C. Hu S. Frey W.H. Ala T.A. Tourtellotte W.W. Peterson P.K. Transforming growth factor beta in Alzheimer’s disease. Clin. Diagn. Lab. Immunol. 1994 1 109 110 7496909 PMC368205
  77. [98]Gray C.W. Patel A.J. Regulation of beta-amyloid precursor protein isoform mRNAs by transforming growth factor-beta1 and interleukin-1beta in astrocytes. Brain Res. Mol. Brain Res. 1993 19 251 256 8412571
  78. [99]Mönning U. Sandbrink R. Banati R.B. Masters C.L. Beyreuther K. Transforming growth factor beta mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Lett. 1994 342 3 267 272 8150082
  79. [100]Wyss-Coray T. Masliah E. Mallory M. McConlogue L. Johnson-Wood K. Lin C. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer’s disease. Nature 1997 389 6651 603 606 9335500
  80. [101]Wyss-Coray T. Lin C. Yan F. Yu G.Q. Rohde M. McConlogue L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001 7 5 612 618 11329064
  81. [103]Lee K.S. Chung J.H. Choi T.K. Suh S.Y. Oh B.H. Hong C.H. Peripheral cytokines and chemokines in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2009 28 4 281 287 19828948
  82. [104]Liao Y. Guan Z. Ravid R. Changes of nuclear factor and inflammatory chemotactic factors in brain of patients with Alzheimer’s disease. Zhonghua Bing Li Xue Za Zhi 2011 40 585 589 22177240
  83. [106]Kiyota T. Yamamoto M. Xiong H. Lambert M.P. Klein W.L. Gendelman H.E. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One 2009 4 7 1 12 PMC2703798 19593388
  84. [107]Kiyota T. Gendelman H.E. Weir R.A. Higgins E.E. Zhang G. Jain M. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer’s disease. Neurobiol. Aging 2013 34 1060 1068 23040664 PMC4011558
  85. [110]Li K. Liu S. Yao S. Wang B. Dai D. Yao L. Interaction between interleukin-8 and methylenetetrahydrofolate reductase genes modulates Alzheimer’s disease risk. Dement. Geriatr. Cogn. Disord. 2009 27 286 291 19246914
  86. [111]Alsadany M.A. Shehata H.H. Mohamad M.I. R GM. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer’s disease. Am. J. Alzheimers Dis. Other Demen. 2012 28 54 61 23242124 PMC10697231
  87. [112]Xia M. Qin S. McNamara M. Mackay C. Hyman B.T. Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer’s disease. Am. J. Pathol. 1997 150 4 1267 1274 9094983 PMC1858175
  88. [113]Bakshi P. Margenthaler E. Laporte V. Crawford F. Mullan M. Novel role of CXCR2 in regulation of gamma-secretase activity. ACS Chem. Biol. 2008 3 12 777 789 19067586
  89. [114]Bakshi P. Margenthaler E. Reed J. Crawford F. Mullan M. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Cytokine 2011 53 2 163 169 21084199
  90. [116]Duan R-S. Yang X. Chen Z-G. Lu M-O. Morris C. Winblad B. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem. Res. 2008 33 6 1085 1089 18095157
  91. [117]Krauthausen M. Kummer M.P. Zimmermann J. Reyes-irisarri E. Terwel D. Bulic B. CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer’s disease model. J. Clin. Invest. 2015 125 1 365 378 25500888 PMC4382235
  92. [118]Tripathy D. Thirumangalakudi L. Grammas P. RANTES upregulation in the Alzheimer’s disease brain: a possible neuroprotective role. Neurobiol. Aging 2010 31 8 16 18440671 PMC2803489
  93. [119]Lee Y.K. Kwak D.H. Oh K.W. Nam S-Y. Lee B.J. Yun Y.W. CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function. Neurobiol. Learn. Mem. 2009 92 3 356 363 19394434
  94. [121]Maier M. Peng Y. Jiang L. Seabrook T.J. Carroll M.C. Lemere C.A. Complement C3 deficiency leads to accelerated amyloid plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 2008 28 25 6333 6341 18562603 PMC3329761
  95. [122]Tyagi E. Fiorelli T. Norden M. Padmanabhan J. Alpha 1-antichymotrypsin, an inflammatory protein overexpressed in the brains of patients with Alzheimer’s disease, induces Tau hyperphosphorylation through c-Jun N-terminal kinase activation. Int. J. Alzheimers Dis. 2013 2013 1 12 PMC3794555 24175110
  96. [123]Eriksson S. Janciauskiene S. Lannfelt L. Alpha1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA 1995 92 2313 2317 7892264 PMC42805
  97. [124]Nilsson L.N. Bales K.R. DiCarlo G. Gordon M.N. Morgan D. Paul S.M. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 2001 21 5 1444 1451 11222634 PMC6762932
  98. [125]Du Y. Bales K.R. Dodel R.C. Liu X. Glinn M.A. Horn J.W. Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J. Neurochem. 1998 70 3 1182 1188 9489740
  99. [126]Hughes S.R. Khorkova O. Goyal S. Knaeblein J. Heroux J. Riedel N.G. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. USA 1998 95 6 3275 3280 9501253 PMC19732
  100. [127]Hsieh H-L. Yang C-M. Role of redox signaling in neuroinflammation and neurodegenerative diseases. BioMed Res. Int. 2013 2013 1 18 PMC3884773 24455696
  101. [128]Desbene C Malaplate-Armand C Youssef I Garcia P Stenger C Sauvee M Critical role of cPLA2 in Abeta oligomer-induced neurodegeneration and memory deficit. Neurobiol Aging 2012 33 6 22188721
  102. [129]Sagy-Bross C. Kasianov K. Solomonov Y. Braiman A. Friedman A. Hadad N. The role of cytosolic phospholipase A2 α in amyloid precursor protein induction by amyloid beta1-42: implication for neurodegeneration. J. Neurochem. 2015 132 559 571 25533654
  103. [130]Heneka M.T. Sastre M. Dumitrescu-Ozimek L. Hanke A. Dewachter I. Kuiperi C. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 2005 128 6 1442 1453 15817521
  104. [131]Sastre M. Dewachter I. Rossner S. Bogdanovic N. Rosen E. Borghgraef P. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 2006 103 2 443 448 16407166 PMC1326151
  105. [132]Li Y. Liu L. Barger S.W. Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003 23 5 1605 1611 12629164 PMC3833596
  106. [133]Quintanilla R.A. Orellana D.I. González-Billault C. Maccioni R.B. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res. 2004 295 1 245 257 15051507
  107. [135]Ghosh S. Wu M.D. Shaftel S.S. Kyrkanides S. LaFerla F.M. Olschowka J.A. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J. Neurosci. 2013 33 11 5053 5064 23486975 PMC3637949
  108. [136]Sheng J.G. Zhu S.G. Jones R.A. Griffin W.S. Mrak R.E. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp. Neurol. 2000 163 2 388 391 10833312 PMC3886634
  109. [137]Mastrangelo M.A. Sudol K.L. Narrow W.C. Bowers W.J. Interferon-γ differentially affects Alzheimer’s disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am. J. Pathol. 2009 175 5 2076 2088 19808651 PMC2774071
  110. [138]Li A. Ceballos-diaz C. DiNunno N. Levites Y. Cruz P.E. Lewis J. IFN-gama promotes tau phosphorylation without affecting mature tangles. FASEB J. 2015 29 10 4384 4398 26156074 PMC6137542
  111. [140]Lee S. Xu G. Jay T.R. Bhatta S. Kim K. Jung S. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J. Neurosci. 2014 34 37 12538 12546 25209291 PMC4160782
  112. [144]De-Paula V.J. Schaeffer E.L. Talib L.L. Gattaz W.F. Forlenza O.V. Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot. Essent. Fatty Acids 2010 82 1 57 60 19726172
  113. [145]Barroso E. del Valle J. Porquet D. Santos A.M. Salvadó L. Rodríguez-Rodríguez R. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice. Biochim. Biophys Acta Mol Basis Dis 2013 1832 8 1241 1248 23507144
  114. [146]Padmanabhan J. Levy M. Dickson D.W. Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer’s disease brain, induces tau phosphorylation in neurons. Brain 2006 129 11 3020 3034 16987932
  115. [148]Sastre M. Walter J. Gentleman S.M. Interactions between APP secretases and inflammatory mediators. J. Neuroinflammation 2008 5 25 1 11 18564425 PMC2442055
  116. [149]Lim G.P. Yang F. Chu T. Chen P. Beech W. Teter B. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J. Neurosci. 2000 20 15 5709 5714 10908610 PMC6772529
  117. [150]Sastre M. Dewachter I. Landreth G.E. Willson T.M. Klockgether T. van Leuven F. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 2003 23 30 9796 9804 14586007 PMC6740896
  118. [152]Tortosa E. Avila J. Pérez M. Acetylsalicylic acid decreases tau phosphorylation at serine 422. Neurosci. Lett. 2006 396 77 80 16386371
  119. [153]McKee A.C. Carreras I. Hossain L. Ryu H. Klein W.L. Oddo S. Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008 1207 225 236 18374906 PMC2587244
  120. [154]Sastre M. Gentleman S.M. NSAIDs: how they work and their prospects as therapeutics in Alzheimer’s disease. Front. Aging Neurosci. 2010 2 1 6 20589102 PMC2893374
  121. [155]Imbimbo B.P. Solfrizzi V. Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front. Aging Neurosci. 2010 2 1 14 20725517 PMC2912027
  122. [156]Tuñón M.J. García-Mediavilla M.V. Sánchez-Campos S. González-Gallego J. Potential of flavonoids as anti-inflammatory agents: modulation of pro-inflammatory gene expression and signal transduction pathways. Curr. Drug Metab. 2009 10 3 256 271 19442088
  123. [158]Wang S. Wang Y-J. Su Y. Zhou W. Yang S. Zhang R. Rutin inhibits β-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines. Neurotoxicology 2012 33 3 482 490 22445961
  124. [160]Leclerc S. Garnier M. Hoessel R. Marko D. Bibb J.A. Snyder G.L. Indirubins inhibit glycogen synthase kinase-3beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 2001 276 251 260 11013232
  125. [161]Gong E.J. Park H.R. Kim M.E. Piao S. Lee E. Jo D. Morin attenuates tau hyperphosphorylation by inhibiting GSK3β. Neurobiol. Dis. 2011 44 2 223 230 21782947 PMC3166962
  126. [162]Baptista F.I. Henriques A.G. Silva A.M. Wiltfang J. da Cruz e Silva OAB. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer’s disease. ACS Chem. Neurosci. 2014 5 2 83 92 24328060 PMC3930994

Cited by

Sorted by citations

Metadata

Authors
Domingues, C., da Cruz e Silva, O. A. B., & Henriques, A. G.
Affiliations
  • Neurosciences and Signalling Laboratory, Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal
  • Neurosciences and Signalling Laboratory, Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, P.O. Box: 3810-193, Aveiro, Portugal
Venue
Current Alzheimer Research
Publisher
Bentham Science Publishers Ltd.
Published
2017-07-18
Volume
14
Issue
8
ISSN
1567-2050
DOI
10.2174/1567205014666170317113606
PMC
PMC5543563
Cited by
203
References
33
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review